Dual antiplatelet therapy: no added benefits for high-risk patients

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1529, 2006-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination Delapril/Manidipine as Antihypertensive Therapy in High-Risk Patients

By Fogari Roberto

Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. : 439-453

Adis International

Access to resources Recommend Favorite

Combination therapy is preferred for the first-line treatment of hypertension in high-risk patients

Drugs & Therapy Perspectives, Vol. 26, Iss. 7, 2010-07 ,pp. : 17-20

Adis International

Access to resources Recommend Favorite

Evidence for the Benefits of the Low-Molecular-Weight Heparin Dalteparin in ‘High-Risk’ Patients with Acute Coronary Syndromes

Heart Drug, Vol. 4, Iss. 3, 2004-08 ,pp. : 157-163

Karger

Access to resources Recommend Favorite

Influenza vaccination benefits high-risk US elderly

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 383, 2002-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Renal Transplantation in High-Risk Patients

By Weimert Nicole A.

Drugs, Vol. 67, Iss. 11, 2007-01 ,pp. : 1603-1627

Adis International

Access to resources Recommend Favorite